


A woman with blonde hair is looking thoughtfully at a molecular model she is holding in her hand. The model consists of black, white, blue, and red spheres connected by white rods. A thick, blue, wavy ribbon graphic is overlaid on the left side of the image, partially obscuring the woman's face and the molecular model.

healthcapital

biotech investments & advisory
worldwide

Biotech Concerto #6
Investment Process
December 2008

- Biotech Investment Characteristics
- Investment Policy
- Investment Team
- Scientific Advisory Board
- Deal Flow
- Attrition Rate
- From 'Screening' to 'Decision'



Source: Aravis Ventures

Guiding Principle

Healthcapital SA is internationally operating, investing into companies which develop promising new drug candidates and/or eliminate bottlenecks in the drug development process. Our objectives are to generate early distributions and high returns. We target high growth biotech businesses that have the potential to deliver a return of 5 times or more of the principal investment in 5 years time frame.

Our portfolio will be structured to balance the levels of risk and to focus on the timing of returns, with a considerable emphasis on investments with low risk and the potential for early returns. These investments will be matched with a portion of the portfolio consisting of companies with a potential of very high returns. Our team will seek to take active positions in portfolio companies, to build value through hands-on oversight, and to trigger significant early exits.

Compelling business opportunities present themselves in many ways. Priority is always given, however, to companies with well-constructed business plans and to individuals referred by partners, entrepreneurs, consultants or other professionals.

Investment Size/Return

Healthcapital SA is participating as co-investor in investment syndicates. We typically encompass investments of an aggregate amount of USD 35m through the life cycle of the emerging growth companies.

Development Stage

Healthcapital SA typically addresses initial investments in private companies whose innovative primary products are in clinical development or the immediately preceding stage. Optimal investment opportunities will have some proof of efficacy in humans prior to the investment.

Industry Focus

- **Biopharmaceutical Companies with proprietary compounds or products that have the potential to become new therapeutics.**
While we will consider any exciting biotech. investment opportunity, we particularly focus on ONC, CNS, TX, immunology, virology, ID, CVS, metabolic diseases, from chemical to biologic compounds.
- **Product Platform Companies that use proprietary technologies to discover new drug candidates for internal development and/or partnerships.**
- **Medtech Companies with cardiovascular, respiratory, and kidney approaches.**



Davide Gai

Trained in Medicine and Business 20 years experience in high tech startups and strategic consulting. Serial high technology entrepreneur.



Marco Baggiolini

Trained in Medicine and Biochemistry Head of Inflammation & Immunology, Sandoz Ltd. Professor of immunology, Theodor Kocher Institute University of Bern, President, University of Lugano

Carlo M. Croce, MD

Professor of Medicine, Director Institute of Genetics, Director of Human Cancer Genetics Program, The Ohio State University. Multiple honors/awards for outstanding contributions in cancer research. Editor-in-Chief American Academy Association for Cancer Research.

Ruggero Fariello, MD

Former Professor and Chair of Neurology at Rush Medical College of Chicago and JMC. Founder of Neuron SpA, which was successfully listed at the Swiss Stock Market.

Joseph S. Gonnella, MD

Dean of Jefferson Medical College in Philadelphia from 1984 to 2000. Has managed worldclass scientists and million dollars of research grants. Is advising a number of countries, including China, to reconstruct their medical education and healthcare system.

Richard A. Insel, MD

Executive Vice President of Research at the Juvenile Diabetes Research Foundation (JDRF). Serves on the National Advisory Allergy and Infectious Diseases Council of the NIH. Cofounder of Praxis Biologics.

Georg Friedrich (Fritz) Melchers, PhD, Dr. h.c mult.


Professor for Immunology at University of Basel. Former director of Basel Institute for Immunology. Co-founder of 4-Antibody Ltd., serves as a scientific advisor and on the Board of Directors of the Company.

Roger James Pomerantz, MD, FACP


Professor for Medicine at Jefferson Medical College Philadelphia. President Tibotec Pharmaceuticals Inc Global Therapeutic Area Head of Virology, Senior Vice President Johnson and Johnson, Inc.

Brian A. Yorke, MA, CPA, EPA

Patent Attorney, former Head of Corporate Intellectual Property at Novartis. Former Chairman Intellectual Property Policy Committee (IPPC) European Federation of Pharmaceutical Industries and Associations (EFPIA)




Attrition Rate







1 Business Case
2 Business Plan







¹ Costs (CHF 60 - 100k) carried by Lead Investor



Contact

Healthcapital SA

Via F. Pelli 2 CH-6900 Lugano / Switzerland

Phone: +41-91-911-8415 Fax: +41-91-911-8414

info@healthcapital.ch

www.healthcapital.ch

Twitter: @healthcapital1